The data and analytic methods used in this study can be made available by the corresponding author upon request to allow for replication or further analysis. Institutional review board approval was not required for this study because it used publicly available, deidentified data extracted from published guideline‐referenced studies and did not involve human subjects or protected health information. This study involved data extraction from the 2021 AHA/ACC/American Society of Echocardiography/CHEST/Society for Academic Emergency Medicine/Society of Cardiovascular Computed Tomography/Society for Cardiovascular Magnetic Resonance Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, 2023 AHA/ACC/American College of Chest Physicians/American Society for Preventive Cardiology/National Lipid Association/Preventive Cardiovascular Nurses Association Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, and 2021 ACC/AHA/Society for Cardiovascular Angiography and Intervention Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideline. Studies referenced within these guidelines included clinical trials, prospective, and retrospective studies, systematic reviews, guideline papers, and studies lacking a specified population were excluded. Data extraction was performed by F.A., J.A., and K.D., with verification conducted by A.A and F.S. Extracted information included study name, publication date, study type, total study population, and the proportion of women included. Clinical trials were segregated for separate analysis. Although most cited studies report participants' sex assigned at birth rather than gender identity, we use the term “gender” throughout this article because the disparities we examine are driven not only by biological differences but also by gender‐based social, structural, and systemic factors that influence study design, enrollment, and interpretation. This study did not involve identifiable human subjects or protected health information and therefore did not require institutional review board approval according to institutional policies.Descriptive statistics were used to summarize the data, including counts and percentages for categorical variables. The proportion of women included in each guideline category was assessed both individually and collectively. A 5‐year average was calculated to depict trends over time. No inferential statistical tests were performed, as the primary aim was to provide a descriptive overview of gender representation trends. To gauge representation, the participation‐to‐prevalence ratio (PPR) was computed for each guideline category, derived by dividing the percentage of women included in the cited studies by the percentage of women within the disease population. The latter percentages were obtained from and .9, 10 A PPR rate <0.8 indicates underrepresentation of women, whereas a rate >1.2 suggests overrepresentation.
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Heart Disease and Stroke Statistics—2024 Update: A Report From the American Heart Association
Furthermore, to evaluate broader trends in how gender and disparities are discussed in cardiovascular research, we performed a PubMed search to assess the number of studies published each year. The search combined terms such as “coronary artery disease,” “chest pain,” “revascularization,” and “ischemic heart disease” with “women,” “gender,” or “disparities.” We then reviewed the annual publication counts to observe how often these topics have been addressed in the literature over time.
RESULTS
The ACC/AHA Guideline papers for chronic coronary disease (CCD), chest pain, and revascularization cited 3209 studies in all. Each citation was carefully examined, removing repeated studies, meta‐analyses, subanalyses, systematic reviews, special reports, and studies that did not mention the number of women included (Figure 1). The final number of studies included in our analysis was 1690 (Table 1). The revascularization guidelines referenced 1085 studies, of which 558 (51.5%) were excluded, resulting in 527 (48.5%) studies included in our analysis.8 Among these included studies, 280 (25.8%) were RCTs. Participation of women in the included studies stood at 29.5%, with 6 of the studies lacking any representation of women. Similarly, the CCD guidelines cited 1260 studies, with 636 (50.5%) being excluded, leaving 624 (49.5%) studies for analysis.7 Within these included studies, 364 (28.8%) were RCTs. Participation of women in the CCD studies was slightly higher at 33.3%, with 7 studies lacking representation of women. In the chest pain guideline, 864 studies were cited, of which 325 (37.5%) were excluded, resulting in 539 (62.5%) studies included in our analysis.6 Among the included studies, 123 (14.2%) were RCTs. Notably, participation of women in chest pain studies was higher at 40%, although 2 studies lacked inclusion of any women.
ACC/AHA indicates American College of Cardiology/American Heart Association.
Summary of the Included Studies and Percentage of Women in Each Guideline Paper
In the chest pain guideline, the trend of participation among women over the years displayed considerable variation, ranging from 14.1% in 1979 to a peak of 71.2% in 2005 (Table S1). The 5‐year average ranged from 36.2% to 45.9% over the past 4 decades, reflecting an overall positive trend in inclusion of women (Figure 2, Table S2). Further analysis focused on the representation of women in RCTs, with the overall percentage of women participating in RCTs being 40.3% (Table S3). Additionally, the trends when comparing non‐RCT versus RCT studies in participation of women have been relatively equal. However, in recent years the gap is increasing, specifically, in 2020 non‐RCT studies enrolled an average of 44.1% women and RCT studies averaged 28.3% in women inclusion (Figure 3).
RCT indicates randomized controlled trial.
In the CCD guideline, the trend of participation of women across the years exhibited variability, ranging from 12.5% in the earliest studies in 1976 to a peak of 47.7% in 2004 (Table S1). Overall, there has been an upward trend in inclusion, with the 5‐year average ranging between 20% and 25% in the 1990s and ∼37.1% to 42.5% in the 2000s (Figure 4). Further analysis focused on the representation of women in RCTs revealed an overall percentage of inclusion of 31.2%. Early RCTs, starting from 1976 and extending into the 1990s, generally exhibited <25% participation of women. The 5‐year average was lowest in the 1990 to 1994 period at 21.1%, compared with 44.5% in the 2000 to 2004 period (Figure 5). Additionally, we compared the trend of women participation for RCT versus non‐RCTs and interestingly we found a large discrepancy between the 2 groupings. Specifically in 2020, non‐RCT studies averaged 51.3% participation of women whereas RCT studies averaged a nominal 26.1% (Figure 5, Table S4).
CCD indicates chronic coronary disease.
CCD indicates chronic coronary disease; and randomized controlled trial.
Within the revascularization guideline, the trend of participation of women exhibited variability, ranging from 0% in 1982 and 1985 to a notable peak of 48.6% in 1997 (Table S1). Over the 4 decades analyzed, the highest 5‐year average of participation that included women was 36.4% observed from 1990 to 1994, and the lowest 5‐year percentage was 29.7% recorded from 2015 to 2019. (Figure 6). When focusing specifically on RCTs within the revascularization guideline, the percentage of women included was 30.2%. However, the trend in RCT participation showed fluctuations, with the highest percentage recorded at 72.9% in 1993 and the lowest at 13.3% in 1984. Overall, the trend in RCT participation demonstrated a downward trajectory in the 5‐year average of participation of women cited in the revascularization guideline paper, and the gap between non‐RCT and RCT studies has grown in recent years. Specifically, in 2020, the average percent of women participation in non‐RCT studies was 45.1% compared with just 27.2% in RCT studies (Figure 7).
RCT indicates randomized controlled trial.
These findings were summarized in Figures 2, 3, 4, 5, 6, 7.
Within the total CVD prevalence among women in the United States estimated at 48.8%, the PPR in CCD studies was 68.2%. The PPR of revascularization studies when compared with the burden of coronary artery disease is 68.8%. In terms of chest pain and angina pectoris statistics, with a prevalence of 48.1% among women in the United States, the PPR in chest pain studies was 83.2% (Table 2).
Participation to Prevalence Ratio of Women in Cardiovascular Studies
To provide context for our findings, we performed a supplementary literature search using PubMed to explore how often gender and disparities are addressed in studies related to chest pain, chronic coronary disease, and revascularization. We used the same keyword strategy described previously and tracked the number of relevant studies published each year. This helped illustrate a growing interest in these issues across the broader cardiovascular research landscape. Specifically, the number of publications surged from 0 in 1985 to >1600 by 2023 (Table S5). This trend highlights growing recognition and acknowledgment of gender disparities in cardiovascular research. However, many of these studies may only mention disparities rather than systematically examining the root causes, suggesting the need for more focused investigations. We plotted the number of studies published using these keywords against the percentage of women's participation in trials (Central Illustration) to explore the relationship between awareness and actual representation.
DISCUSSION
To our knowledge, this study is the first to comprehensively assess the inclusion of women in studies used to develop guidelines for the management of ischemic heart disease. Our findings reveal persistent and significant underrepresentation of women in all ACC/AHA guidelines pertaining to chest pain, chronic coronary artery disease, and revascularization with no discernible improvement observed over time. These findings emphasize the urgent need to recruit more women into pivotal RCTs, which are most important in informing clinical guidelines. Although most clinical trials report sex assigned at birth rather than gender identity, we use the term gender throughout this article to emphasize the influence of gender‐based assumptions and biases on study design, enrollment, and implementation. This approach highlights how both recognized and unrecognized societal and systemic factors can contribute to the underrepresentation of women in cardiovascular research. Additionally, it is imperative for physicians to recognize and address the fact that the low rate of inclusion of women may affect the care of 51% of the population.
Our analysis of 1690 studies spanning from 1971 to 2022, reveals a consistent pattern of notably lower participation of women across all 3 guideline areas, with rates of 29.5%, 33.3%, and 40% for revascularization, chronic coronary artery disease, and chest pain guidelines, respectively. Our findings align with prior research highlighting gender ratio discrepancies in cardiac trials.11 For instance, Jin et al.'s study of 740 cardiovascular clinical trials from 2010 to 2017 found that women accounted for only 38.2% of participants.12 Similarly, Tahhan et al.'s research on heart failure trials demonstrated ongoing gender disparities post‐2001, with a PPR <0.8 for older patients and women.13
Furthermore, we found complete absence of participation among women in 15 studies cited in the guidelines, 5 of which explicitly focused on men only, predominantly conducted before 1990 by the Veterans Affairs Office of Research. These findings underscore the historical and persistent underrepresentation of women in cardiovascular research, raising concerns regarding the generalizability and effectiveness of treatments primarily tailored to men. The implications of gender disparities in clinical trials extend beyond mere representation; they affect clinical decision‐making and guideline development. Scott et al.'s investigation found disease‐specific variations in representation of women within trials used to support Food and Drug Administration‐approved cardiovascular drugs, highlighting the potential consequences of underrepresentation on evidence‐based practice.14 These findings emphasize the critical need for increased women's representation in cardiovascular research to ensure more equitable and effective treatment strategies for all patients.
Efforts to address these disparities have been ongoing, notably with the passage of the National Institutes of Health Revitalization Act in 1993, which aimed to ensure equitable inclusion of women and underrepresented populations in clinical research.15, 16 This spurred a notable surge in advocacy aimed at enhancing participation of women in large clinical trials and a substantial increase in publications addressing these gaps. These efforts are also evident within the guideline papers themselves. Notably, guideline papers on chest pain and CCD have dedicated sections highlighting these crucial differences. Moreover, the significance of disparities in care was underscored as a key takeaway in the top 10 messages of the revascularization and chest pain guidelines.6, 8 These efforts acknowledging biases within guidelines represent important steps toward addressing gender disparities in cardiovascular research and clinical practice.
A critical question remains: does this heightened awareness effectively translate into increased representation of women as CVD research progresses? The trend of inclusion reflected in our study fails to show a parallel rise (central illustration). Understanding the factors contributing to underrepresentation of women in clinical trials is essential for effective interventions. Melloni et al.'s study highlighted the impact of clinical indication on enrollment of women, showing higher participation rates in trials focused on hypertension and diabetes compared with coronary artery disease and heart failure.16 Additionally, differences in gender preferences, perceptions, and behaviors toward trial participation underscore the need for gender‐specific recruitment approaches. Previous research indicates that women are more often enrolled in primary prevention studies of CVD rather than in secondary prevention, possibly due to physician bias in participant selection and the later onset of CVD in women compared with men.17, 18, 19, 20, 21, 22 However, other evidence suggests that women are also underrepresented even in primary prevention trials, such as the early statin trials (eg, WOSCOPS [West of Scotland Coronary Prevention Study] and AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study])23, 24 Moreover, studies suggest that women's lower willingness to participate in cardiac trials, particularly RCTs, is influenced by concerns about added risk and time inconvenience.25, 26 However, we should counter the belief that women are reluctant to participate in clinical studies. Evidence shows that women enrolled without hesitation in significant numbers in studies such as the WHI (Women's Health Initiative), WISE (Women's Ischemia Syndrome Evaluation), and the St. James WTH (Women Take Heart) Project.27, 28, 29 However, much of the existing literature is not directed at women. This lack of focus on women may also stem from a shortage of female investigators, which leads to less consideration of women‐specific concerns and factors that would encourage their participation. These differences in gender highlight the importance of tailoring trial recruitment strategies to address gender‐specific behaviors and perceptions.
Acknowledging the limitations of our study, the exclusion of systematic reviews, guideline papers, statements, and studies without a specified population could result in the absence of relevant data that may have provided additional information. Additionally, some individual years have peaks much higher than the average percentage of women; however, this is likely attributable to the limited number of studies published that year, with a few studies focusing predominantly on women, thereby skewing the annual data. This highlights the importance of evaluating 5‐year averages as seen in Figures 2, 4, and 6, which provide a more stable and representative trend over time. Also, we focused on only 3 guidelines papers that we believed most relevant in patients with coronary artery disease. It is also important to note that the guidelines do not include every study considered during their development and we did not review and include the full evidence tables that often contain additional studies. Because of this, our analysis may not reflect the complete body of evidence used by the guideline committees. Lastly, the calculated PPRs were based on US estimates of disease prevalence and may not fully reflect the current burden. We also acknowledge that most included studies report sex assigned at birth; our use of gender throughout the article emphasizes the social and systemic factors influencing participation rather than a direct measurement of gender identity.
Conclusions
In conclusion, our findings emphasize the urgent necessity for sustained proactive measures to address gender disparities by including women in practice‐changing cardiovascular research. Achieving gender parity in trial enrollment is imperative for ensuring equitable health care delivery and improving cardiovascular outcomes for all individuals. Future research should prioritize identifying barriers that decrease representation of women in ischemic heart disease trials to promote evidence‐based, gender‐inclusive clinical practice.
Sources of Funding
None.
Disclosures
Martha Gulati: Consultant Fees/Honoraria: Esperion, Medtronic Inc.
Supporting information
Tables S1–S5
PN
Dr. Phoo pwint Nandar
Cardiology · Advanced Heart Failure & TransplantationMetroHealth Medical Centerphoopwint